Mylan Pharmaceuticals, the subsidiary of Pharma giant Mylan NV has launched Gilead Sciences' Sovaldi or sofosbuvir 400 mg tablets to treat chronic hepatitis-C infection.
Pharma giant Mylan NV has announced that its subsidiary Mylan Pharmaceuticals has launched Gilead Sciences' Sovaldi (sofosbuvir 400 mg tablets) in India.
Sovaldi is used for the treatment of chronic hepatitis-C infection as a component of a combination anti-viral treatment.
About 12 million people are chronically infected with hepatitis-C in India, as per a rough estimate, said Mylan in a release.
In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India.
Significantly, Rajiv Malik, President, Mylan said that the company have a history of partnering with Gilead to tackle key public health issues in India and across the globe, beginning with expanding access to high quality and affordable HIV/AIDS anti-retrovirals.
"We are proud to continue our work together with the launch of Sovaldi as it supports our joint commitment to meeting the unmet medical needs of patients in India," noted Malik.
Gregg Alton, Executive Vice-President, Corporate and Medical Affairs, Gilead Sciences said it makes an important milestone in the company's ongoing effort to make its hepatitis-C medicines accessible to as many patients, in as many places, as quickly as possible.
Reportedly, Sovaldi is sold by Mylan's dedicated sales force as part of its Hepato Care segment.